Cited by 511Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombi

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Open access

Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.·2016·Journal for ImmunoTherapy of Cancer

DOI 10.1186/s40425-016-0152-yPMC PMC4986340

Open this paper in CoChat — free account Open PDF

Abstract

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s40425-016-0152-y

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Histologic presentation of case 1. Endomyocardial biopsy shows interstitial fibrosis with some interstitial lymphocytes. Signs of hypertrophy are detectableCC BY · PubMed Central

Fig. 2 Histologic presentation of case 5. a H&E stain of the endomyocardial biopsy shows patchy lymphohistiocytic infiltrates associated with myocyte damage, diagnostic for lymphocytic myocarditis. b IHC stain for CD3 highlights in brown T cells within the inflammatory infiltrate (c) IHC stain for CD8 highlights in brown T cells within the inflammatory infiltrate (d) IHC stain for CD68 shows many histiocytes/macrophages within the myocardial inflammationCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Show all 37 references

Research works printed but not linked: 1

Larkin J, D’Angelo S, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma. Pigment Cell Melanoma Res. 2016;28:789.

Sorted by citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,498
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Self-citation
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
A population-based study of cardiovascular disease mortality risk in US cancer patients
Sturgeon, K. M., Deng, L., Bluethmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., Kelly, S. P., & Zaorsky, N. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz766 · Cited by 938
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Cardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Self-citation
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J. R., Andrews, S., Armand, P. A., Bhatia, S., Budde, L. E., Costa, L. J., Davies, M. J., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 490
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 435
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giaccone, G., Kim, C., Thompson, J., McGuire, C., Kallakury, B., Chahine, J. J., Manning, M. A., Mogg, R., Blumenschein, W. M., Tan, M. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30062-7 · Cited by 417
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T., Grimm, M., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 334
Self-citation
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 307
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 254
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 242
Self-citation
Cardiovascular Toxicities of Immune Checkpoint Inhibitors
Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 231
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
Luo, X., Wu, K., & He, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01968-w · Cited by 207
Smoldering myocarditis following immune checkpoint blockade
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L. J., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 202
Cancer Treatment–Induced Arrhythmias
Buza, V., Rajagopalan, B., & Curtis, A. B. (2017) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.117.005443 · Cited by 194
Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., Sultan, D., Bredemeyer, A., Bajapa, G., Feng, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.062551 · Cited by 187
The Innate Immune System in Chronic Cardiomyopathy: A European Society of Cardiology (Esc) Scientific Statement from the Working Group on Myocardial Function of the ESC
Frantz, S., Falcão‐Pires, I., Balligand, J., Bauersachs, J. K., Brutsaert, D. L., Ciccarelli, M., Dawson, D. K., Windt, L. J. D., Giacca, M., Hamdani, N., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1138 · Cited by 194
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3750 · Cited by 179
“The cases are illustrated in Table 3 below [95-102].”
Background
Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis: A Narrative Review
Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
D’Souza, M., Nielsen, D. L., Svane, I. M., Iversen, K. K., Rasmussen, P. V., Madelaire, C., Fosbøl, E. L., Køber, L., Gustafsson, F., Andersson, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa884 · Cited by 176
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation
Mao, D., Hu, F., Yi, Z., Kenry, K., Xu, S., Yan, S., Luo, Z., Wu, W., Wang, Z., Kong, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2712 · Cited by 153
Cardiotoxicity of Immune Checkpoint Inhibitors
Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 154
Electroimmunology and cardiac arrhythmia
Grune, J., Yamazoe, M., & Nahrendorf, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00520-9 · Cited by 161
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 147
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis
written on behalf of the AME Academic Lung Cancer Cooperation Group, Hu, Y., Zhang, Q., Li, H., Michot, J., Liu, H., Zhan, P., Lv, T., & Song, Y. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.12.10 · Cited by 136
Inflammation in kidney repair: Mechanism and therapeutic potential
Fu, Y., Yu, X., Li, H., Chen, A., & Dong, Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108240 · Cited by 138
Clinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 137
Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 130
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
Tocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 132
Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area
Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 124
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 128
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 126
Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
Ji, C., Roy, M. D., Golas, J., Vitsky, A., Ram, S., Kumpf, S. W., Martin, M. T., Barletta, F., Meier, W. A., Hooper, A. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4083 · Cited by 122
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119
Checkpoint Inhibitors
Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 123
Self-citation
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein
Uversky, V. N., Redwan, E. M. M. M., Makis, W., & Rubio‐Casillas, A. (2023) · Vaccines · doi:10.3390/vaccines11050991 · Cited by 127
Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
Champion, S. N., & Stone, J. R. (2019) · Modern Pathology · doi:10.1038/s41379-019-0363-0 · Cited by 116
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 109
Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
Laenens, D., Yu, Y., Santens, B., Jacobs, J., Beuselinck, B., Bechter, O. E., Wauters, E., Staessen, J. A., Janssens, S. P., & Aelst, L. N. L. V. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01808 · Cited by 111
Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
Michel, L., Rassaf, T., & Totzeck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.15 · Cited by 110
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
Dudnik, E., Moskovitz, M. T., Daher, S., Shamai, S., Hanovich, E., Grubstein, A., Shochat, T., Wollner, M., Bar, J., Merimsky, O., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.015 · Cited by 106
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 106
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppler, A. M., Spain, L. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.013 · Cited by 105
Self-citation
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
Chitturi, K. R., Xu, J., Araujo‐Gutierrez, R., Bhimaraj, A., Guha, A., Hussain, I., Kassi, M., Bernicker, E., & Trachtenberg, B. H. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.013 · Cited by 104
Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 102
Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin
Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000239 · Cited by 96
Cardiotoxicity of Anticancer Therapeutics
Dong, J., & Chen, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00009 · Cited by 95
Identifying and managing the adverse effects of immune checkpoint blockade
Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 96
Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology
Chen, D., Huang, W., Wu, V. C., Chang, W., Chen, J., Chuang, C., & Chu, P. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.025 · Cited by 96
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 101
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 95
Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation
Bockstahler, M., Fischer, A., Goetzke, C. C., Neumaier, H. L., Sauter, M., Kespohl, M., Müller, A., Meckes, C., Salbach, C., Schenk, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043171 · Cited by 89
Cardiotoxicity of Immune Checkpoint Inhibitors
Zhang, L., Jones‐O’Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A., Lyon, A. R., & Neilan, T. G. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0731-6 · Cited by 89
Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling
Xia, W., Zou, C., Chen, H., Xie, C., & Hou, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02778-2 · Cited by 90
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 89
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
Atallah‐Yunes, S. A., Kadado, A. J., Kaufman, G. P., & Hernández-Montfort, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02927-x · Cited by 87
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients
Sarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Bello, M. G. D., Rijavec, E., Barletta, G., Rossi, G., Biello, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0452 · Cited by 88
A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma
Ma, H., Chang, H., Yang, W., Lu, Y., Hu, J., & Jin, S. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1123-y · Cited by 87
Cardiovascular Complications Associated With Novel Cancer Immunotherapies
Jain, V., Bahia, J., Mohebtash, M., & Barac, A. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0532-8 · Cited by 87
Non-ischemic dilated cardiomyopathy and cardiac fibrosis
Cojan-Minzat, B. O., Zlibut, A., & Agoşton-Coldea, L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09940-0 · Cited by 87
Managing cardiotoxicity associated with immune checkpoint inhibitors
Upadhrasta, S., Elias, H., Patel, K., & Zheng, L. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.02.004 · Cited by 83
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
Agrawal, N., Khunger, A., Vachhani, P. J., Colvin, T. A., Hattoum, A., Spangenthal, E. J., Curtis, A. B., Dy, G. K., Ernstoff, M. S., & Puzanov, I. J. (2019) · Case Reports in Oncology · doi:10.1159/000498985 · Cited by 81
Exploring immune checkpoints as potential therapeutic targets in atherosclerosis
Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx248 · Cited by 81
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure
Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 77
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer
Rocca, C., Soda, T., Francesco, E. M. D., Fiorillo, M., Moccia, F. D., Viglietto, G., Angelone, T., & Amodio, N. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04498-5 · Cited by 80
Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy
Tajmir-Riahi, A., Bergmann, T., Schmid, M., Agaimy, A., Schuler, G., & Heinzerling, L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000190 · Cited by 78
Self-citation
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 80
Self-citation
PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction
Xia, W., Chen, H., Chen, D., Ye, Y., Xie, C., & Hou, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001293 · Cited by 77
Supportive care for patients undergoing immunotherapy
Rapoport, B. L., Eeden, R. I. V., Sibaud, V., Epstein, J. B., Klastersky, J. A., Aapro, M., & Moodley, S. D. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3802-9 · Cited by 77
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 76
Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment
Gergely, T. G., Kucsera, D., Tóth, V. É., Kovács, T., Sayour, N. V., Drobni, Z. D., Ruppert, M., Petrovich, B., Ágg, B., Onódi, Z., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15984 · Cited by 75
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
Reuben, A., de Macêdo, M. P., McQuade, J. L., Joon, A. Y., Ren, Z., Calderone, T. L., Conner, B., Wani, K., Cooper, Z. A., Tawbi, H. A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1361097 · Cited by 73
Self-citation
Fatal Myocarditis Following Treatment with the PD ‐1 Inhibitor Nivolumab
Matson, D. R., Accola, M. A., Rehrauer, W. M., & Corliss, R. F. (2017) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13633 · Cited by 72
Immune checkpoint inhibitor-related myocarditis
Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 71
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 73
A review of serious adverse effects under treatment with checkpoint inhibitors
Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 67
Self-citation
PD-1 checkpoint inhibition: Toxicities and management
Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 68
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01002-w · Cited by 66
Melanoma and Immune Checkpoint Inhibitors
Furue, M., Ito, T., Wada, N. A., Wada, M., Kadono, T., & Uchi, H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0676-z · Cited by 67
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
Zotova, L. (2023) · Diagnostics · doi:10.3390/diagnostics13071243 · Cited by 64
Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy
Sobol, I., Chen, C. L., Mahmood, S., & Borczuk, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0447-oa · Cited by 67
Toxicity profiles of immunotherapy
Cousin, S., Sénéschal, J., & Italiano, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.005 · Cited by 63
Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy
de Almeida, D. V. P., Gomes, J. R., Haddad, F. J., & Buzaid, A. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000217 · Cited by 62
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 70
Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review
Pradhan, R., Nautiyal, A., & Singh, S. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.025 · Cited by 63
An immunogenomic signature for molecular classification in hepatocellular carcinoma
Zhuang, W., Sun, H., Zhang, S., Zhou, Y., Weng, W., Wu, B., Ye, T., Huang, W., Lin, Z., Shi, L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.024 · Cited by 61
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 63
Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches
Landolt, L. Z., Spagnoli, G. C., Hertig, A., Brochériou, I., & Marti, H. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa301 · Cited by 61

Authors: Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J.
Affiliations: Universitätsklinikum Erlangen (DE)
Dana-Farber Cancer Institute (US)
University of Chicago (US)
The University of Texas MD Anderson Cancer Center (US)
Paracelsus Medizinische Privatuniversität (DE)
Sidney Kimmel Comprehensive Cancer Center (US)
Corresponding author: Heinzerling, Lucie
ORCID: Heinzerling, Lucie
Ott, Patrick A.
Hodi, F. Stephen
Husain, Aliya N.
Tawbi, Hussein
Pauschinger, Matthias
Gajewski, Thomas F.
Lipson, Evan J.
Luke, Jason J.
Venue: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Published: 2016-08-16
Volume: 4
Issue: 1
Pages: 50-50
ISSN: 2051-1426 (ISSN-L)
DOI: 10.1186/s40425-016-0152-y
PMC: PMC4986340
OpenAlex: W2478478625
Cited by: 511
References: 37
Citations by year: 2026: 21 · 2025: 29 · 2024: 34 · 2023: 43 · 2022: 50 · 2021: 77 · 2020: 78 · 2019: 64 · 2018: 61 · 2017: 50 · 2016: 2
FWCI: 31.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
Funders: Melanoma Research Alliance
Celldex Therapeutics
National Institutes of Health
Genentech
National Cancer Institute (K12CA139160)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords: immune-related cardiotoxicity, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, ipilimumab, nivolumab, pembrolizumab, myocarditis, pericarditis, heart failure, cardiomyopathy, myocardial fibrosis, atrioventricular block, corticosteroid therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks